In the unmatched cohort, patients receiving semaglutide exhibited significantly lower age, left ventricular ejection fraction (LVEF), and NT-proBNP levels, along with higher BMI, triglycerides, and a greater prevalence of diabetes mellitus type 2 compared to the unmatched control cohort (all p < 0.05). This evidence concerns the gene NPPB and type 2 diabetes mellitus.